[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602293":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":48,"collaborators":50,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":78,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University Hospital, Tours","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PHArmacoKinetics of methYLphenidate in adult patients with ADHD","EXPERIMENTAL","PHArmacoKinetics of methYLphenidate in adult patients with ADHD: patients with OBesity.\n\nPHArmacoKinetics of methYLphenidate in adult patients with ADHD: patients without OBesity.",[13],"Drug: PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.","The pharmacological intervention, which will be the same for all patients in the study, will consist in administering MPH at CIC 1415 (URHC of Tours) in the form of Prolonged Release at the patient's usual dosage, in the early morning.\n\nPharmacokinetic study with repeated measurements at T0 (just before MPH administration) then T30 minutes, T1 hour, T2h, T3h, T4h, T6h, T8h (8 measurements) after MPH administration, in 15 patients with ADHD and obesity (BMI≥30 kg\u002Fm2) and in 15 patients with ADHD but without obesity (BMI\\\u003C30 kg\u002Fm2).",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Paul BRUNAULT, MD and PhD","CONTACT","02 18 37 05 81","paul.brunault@univ-tours.fr",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Valérie GISSOT, MD","02 34 37 96 53","valerie.gissot@univ-tours.fr",[32],{"facility":33,"status":20,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Center Hospitalier Régional Universitaire of TOURS","Tours","Indre-et-Loire","37044","France","FR",{"type":40,"coordinates":41},"Point",[42,43],0.70398,47.39484,{"lat":43,"lon":42},[46,47],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":6},"Fondation de l'Avenir","100602293","phase-4-pharmacokinetics-of-methylphenidate-in-adult-patients-with-attention-deficit-hyperactivity-disorder-100602293",false,"NCT07121621","PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit \u002FHyperactivity Disorder","PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit \u002FHyperactivity Disorder: Comparison Between Patients With and Without OBesity","PHACYLOB","Inclusion Criteria:\n\n* Adults aged 18 and over\n* Diagnosis of ADHD by a psychiatrist, based on DSM-5 criteria (ADHD mixed form, predominantly inattentive or predominantly hyperactive\u002Fimpulsive)\n* Treatment with methylphenidate LP (Ritaline) with a stable dosage for at least two weeks.\n* BMI inclusion criteria: (1) for obese group: BMI ≥ 30 kg\u002Fm2; (2) for non-obese group: BMI \\\u003C 30 kg\u002Fm2.\n* Participant affiliated to a social security scheme\n* Written consent signed by participant\n\nExclusion Criteria:\n\n* Contraindications to methylphenidate treatment\n* Treatment with an oral or nasal decongestant vasoconstrictor; association with a non-selective MAOI antidepressant.\n* Treatment with a proton pump inhibitor within the last 2 weeks.\n* Severe cognitive impairment (clinical evaluation)\n* Severe alcohol use disorder, i.e. at least 6 DSM-5 criteria for substance use disorder (clinical evaluation)\n* Known prior renal impairment\n* Pregnant or breast-feeding women\n* Female patients of childbearing age without at least one acceptable contraceptive method (see definition in Appendix 1)\n* Patients under legal protection\n* Inability of the patient to self-assess the intensity of ADHD symptoms","ALL","18 Years",{"count":64,"type":65},30,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","PHACYLOB PHArmaCokinetics of methYLphenidate in adult patients with Attention-Deficit Hyperactivity Disorder (ADHD) : comparison between patients with and without OBesity.\n\nIts aim is to determine whether, for a comparable treatment dose, there are differences in the pharmacokinetic of methylphenidate between ADHD patients with obesitý and ADHD patients but without obesitý. More specifically, we will assess whether blood concentrations of methylphenidate (MPH; long acting form) are significantly higher or lower in either group at different times of the day.\n\nTo meet this objective, we are conducting this pharmacokinetic clinical trial with blood sampling and repeated clinical measurements just prior to MPH administration (= at T0) and then, at different times after administration, i.e. at times (T): T 30 minutes, T 1 hour, T2h, T3h, T4h, T6h, T8h after MPH administration. As far as MPH is concerned, this is the usual treatment. However, we may hypothesize that the distribution in the body may differ according to weight: hence the interest of this study",[71,72,73,74],"Attention Deficit Hyperactivity Disorder (ADHD)","Obesity (Body Mass Index &Amp;Amp;gt;30 kg\u002Fm2)","Methylphenidate","Obesity &Amp; Overweight",[73,71,76,77],"Obesity","Pharmacokinetics","NOT_YET_RECRUITING","2025-08-12",{"date":81,"type":82},"2025-08-13","ACTUAL",{"date":84,"type":65},"2025-09-01",{"date":86,"type":65},"2026-09-02",{"name":5,"class":6},1]